Elevidys has been developed by the company in collaboration with Roche ( RHHBY - Free Report ). Sarepta and Roche entered into a licensing agreement in 2019 to develop and commercialize Elevidys jointly. Per the agreement, Roche has exclusive rights to launch and commercialize the gene therapy in ex-U.S. markets. As part of the agreement, Sarepta will record collaboration revenues on the ex-U.S. sales made by Roche.